Study and Follow-up of Multiple Endocrine Neoplasia Type 1

Plain-language summary

This study follows the long-term course of Multiple Endocrine Neoplasia Type 1 (MEN1) through a follow-up survey. It can include symptomatic individuals living in France with a confirmed MEN1 diagnosis, as well as asymptomatic people carrying a MEN1 mutation. It is a non-phase study that is currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Centre Hospitalier Universitaire Dijon

Intervention

survey for long-term follow-up of the disease

Start date

7/1/2012

Estimated completion

7/1/2031

Countries

France

Related genes

Locations

• Dijon, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

\- Symptomatic individuals with a confirmed diagnosis of MEN1 and who live in France.

Patients with the following characteristics will also be included in the cohort:

* At least two of the three cardinal clinical lesions (parathyroid, pancreas, pituitary),
* OR an isolated known lesion of the disease, cardinal or not (parathyroid, pancreas, pituitary, adrenal, thymus, bronchus, tumour of the central nervous system) associated with a mutation of the MEN1 locus on chromosome 11q13,
* OR an isolated lesion, cardinal or not (parathyroid, pancreas, pituitary, adrenal, thymus, bronchus, tumour of the central nervous system) in an individual with a confirmed family history of MEN1.

asymptomatic patients who carry a characteristic mutation of MEN1. Current knowledge suggests that these patients will develop symptoms during their follow-up.

Exclusion Criteria:

patients who present a single-organ genetic endocrine disease associated with another genetic syndrome (familial isolated pituitary adenoma FIPA, familial isolated hyperparathyroidism FIHP)